Alliances

Cellastra licensed the proprietary AAV6.2FF gene vector technology from the University of Guelph in Ontario (US patent 10,806,802 B2).  This vector combined with the proprietary transgene technology being developed by Cellastra (US Patent 11,891,429 B2) for a longer half-life version of ensereptide in Cellexa should revolutionize the treatment of wound healing. 

Cellastra has formed alliances with numerous contract research and manufacturing organizations to inform the evolving development program for Cellexa to IND and beyond. 

Cellastra seeks qualified investors and or development partners to help us launch the Cellexa program and validate the concepts. 

Cellastra welcomes input from individuals or organizations wishing to explore alliances.  Please contact one of the following individuals:
 
If you have any questions regarding Alliances, Business Development, or M & A, please email: